{"schema_version":"secwatch.filing_event.v1","accession":"0000200406-23-000059","form_type":"8-K","ticker":"JNJ","cik":"0000200406","company_name":"JOHNSON & JOHNSON","filed_at":"2023-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.657102+00:00","generated_at":"2026-06-16T05:24:25.665457+00:00","sec_items":["5.02","5.07"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Thibaut Mongon leaving JNJ executive roles after Kenvue IPO; annual meeting results announced","bullets":["Thibaut Mongon to step down as EVP, WW Chairman Consumer Health and Executive Committee member upon Kenvue IPO closing; remains Kenvue CEO.","All 12 Johnson & Johnson director nominees elected at annual meeting; each received >1.68B votes in favor.","Shareholders approved advisory say-on-pay (1.685B for, 123M against) and set frequency at 1 year until 2029.","Ratification of PwC as independent auditor for FY2023 passed with 2.049B votes for, 119M against.","Two shareholder proposals—Vaccine Pricing Report and Extended Patent Exclusivities Report—were rejected by wide margins."],"urls":{"canonical":"https://secwatch.observer/filing/0000200406-23-000059","json":"https://secwatch.observer/filing/0000200406-23-000059.json","markdown":"https://secwatch.observer/filing/0000200406-23-000059.md","text":"https://secwatch.observer/filing/0000200406-23-000059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/200406/000020040623000059/0000200406-23-000059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/200406/000020040623000059/jnj-20230427.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T05:24:25.665457+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"68dfd02ebd","claim":"Thibaut Mongon departed as Executive Vice President, Worldwide Chairman, Consumer Health at JOHNSON & JOHNSON.","evidence_excerpt":"Upon the closing of the initial public offering of Kenvue Inc., Thibaut Mongon will cease to be Executive Vice President, Worldwide Chairman, Consumer Health and member of the Executive Committee of Johnson & Johnson and will continue his role as Chief Executive Officer of Kenvue Inc.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/200406/000020040623000059/0000200406-23-000059-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will cease to be"},{"label":"Role","value":"Executive Vice President, Worldwide Chairman, Consumer Health"}],"fact_type":"executive_change"},{"claim_id":"1723f1ab9830ade45801a5b283aac2287b43d971","claim":"JOHNSON & JOHNSON shareholders approved Advisory Vote to Approve Named Executive Officer Compensation at the 2023-04-27 meeting.","evidence_excerpt":"Advisory Vote to Approve Named Executive Officer Compensation: For Against Abstained Non-Votes 1,685,320,654 123,275,647 11,076,730 353,172,322","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/200406/000020040623000059/0000200406-23-000059-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-04-27"}],"fact_type":"shareholder_vote"},{"claim_id":"2ffedd3fd2a742abe1458e735204dab9b5698589","claim":"JOHNSON & JOHNSON shareholders approved Advisory Vote on the Frequency of Voting to Approve Named Executive Officer Compensation at the 2023-04-27 meeting.","evidence_excerpt":"Advisory Vote on the Frequency of Voting to Approve Named Executive Officer Compensation: For 1 Year For 2 Years For 3 Years Abstained Non-Votes 1,785,566,411 4,955,319 22,089,730 7,061,571 353,172,322","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/200406/000020040623000059/0000200406-23-000059-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-04-27"}],"fact_type":"shareholder_vote"},{"claim_id":"53af3716ee84d54709c224e827b78feb2aa64a74","claim":"JOHNSON & JOHNSON shareholders rejected Shareholder Proposal - Impact of Extended Patent Exclusivities on Product Access at the 2023-04-27 meeting.","evidence_excerpt":"Shareholder Proposal - Impact of Extended Patent Exclusivities on Product Access: For Against Abstained Non-Votes 258,032,003 1,530,773,877 30,867,151 353,172,322","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/200406/000020040623000059/0000200406-23-000059-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"failed"},{"label":"Meeting","value":"2023-04-27"}],"fact_type":"shareholder_vote"},{"claim_id":"85917c6a00bfd02bb776bd3ffe0dfe4191233f46","claim":"JOHNSON & JOHNSON shareholders approved Election of Directors at the 2023-04-27 meeting.","evidence_excerpt":"Election of Directors: Shares For Shares Against Shares Abstain Non-Votes D. Adamczyk 1,786,272,387 16,426,067 16,974,577 353,172,322 M. C. Beckerle 1,789,457,274 13,764,941 16,450,816 353,172,322 D. S. Davis 1,756,303,275 46,470,790 16,898,966 353,172,322 J. A. Doudna 1,789,027,330 14,257,035 16,388,666 353,172,322 J. Duato 1,688,009,715 120,870,955 10,792,361 353,172,322 M. A. Hewson 1,773,472,628 29,649,436 16,550,967 353,172,322 P. A. Johnson 1,804,950,345 9,856,598 4,866,088 353,172,322 H. Joly 1,772,344,027 30,395,092 16,933,912 353,172,322 M. B. McClellan 1,788,586,733 14,265,282 16,821,016 353,172,322 A. M. Mulcahy 1,698,043,017 104,917,215 16,712,799 353,172,322 M. A. Weinberger 1,788,359,732 14,280,263 17,033,036 353,172,322 N. Y. West 1,793,769,456 9,125,005 16,778,570 353,172,322","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/200406/000020040623000059/0000200406-23-000059-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-04-27"}],"fact_type":"shareholder_vote"},{"claim_id":"88a61e16b87f85cc33d030f8a98754ae26d402e1","claim":"JOHNSON & JOHNSON shareholders approved Ratification of Appointment of PricewaterhouseCoopers LLP as the Company's Independent Registered Public Accounting Firm for 2023 at the 2023-04-27 meeting.","evidence_excerpt":"Ratification of Appointment of PricewaterhouseCoopers LLP as the Company's Independent Registered Public Accounting Firm for 2023 : For Against Abstained Non-Votes 2,048,852,179 118,621,657 5,371,517 (0)","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/200406/000020040623000059/0000200406-23-000059-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-04-27"}],"fact_type":"shareholder_vote"},{"claim_id":"ec8dd08817c10e9b63c22f883256eae2f66199c7","claim":"JOHNSON & JOHNSON shareholders rejected Shareholder Proposal - Vaccine Pricing Report at the 2023-04-27 meeting.","evidence_excerpt":"Shareholder Proposal - Vaccine Pricing Report: For Against Abstained Non-Votes 569,515,836 1,223,800,230 26,356,965 353,172,322","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/200406/000020040623000059/0000200406-23-000059-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"failed"},{"label":"Meeting","value":"2023-04-27"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}